PARIS, Oct 16 (Reuters) - French unions have called on workers at Sanofi (SASY.PA), opens new tab to strike from Thursday to protest a planned sale of the pharmaceutical group's consumer health ...

“We really welcome that there are more players to come because it increases the size of the playing field,” Thomas Triomphe, Sanofi’s executive vice president for vaccines, said of the ...

Sanofi SAN-0.92%decrease; red down pointing triangle is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual forward-looking statements. We would like to remind you that information presented in this ...

while we saw steady growth of 67% for our launch medicines as well as volume-driven growth by Dupixent," CEO Paul Hudson remarked. Sanofi's (SNY) bottom line improved ~12% YoY to €2.86 earnings ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

Paul Hudson Chief Executive Officer, Sanofi “We are proud of what Opella and its inspired people have already accomplished. We are confident that the future of Opella will be even brighter.

Sanofi shares were down 0.5% in early trade. Speaking to reporters on Monday about its choice of buyer, chief executive Paul Hudson said: "We chose the group with the best capabilities and people ...

PARIS, October 17, 2024--(BUSINESS WIRE)--Regulatory News: Sanofi and Orano Med ... patients’ lives and improve their quality of life. "We are excited to partner with Orano in establishing ...

Paul Hudson CEO, Sanofi “We are excited to partner with Orano in establishing a French pioneer that unites our respective expertise in biopharma and nuclear technology to drive groundbreaking ...